Theratechnologies Inc. (NASDAQ:THTX) Short Interest Up 26.8% in October

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 43,000 shares, an increase of 26.8% from the October 15th total of 33,900 shares. Based on an average daily trading volume, of 33,400 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.2% of the company’s stock are short sold.

Theratechnologies Stock Down 0.8 %

NASDAQ:THTX opened at $1.21 on Friday. The company’s 50 day moving average price is $1.25 and its 200-day moving average price is $1.31. Theratechnologies has a 52 week low of $1.08 and a 52 week high of $2.58. The stock has a market cap of $55.64 million, a price-to-earnings ratio of -12.80 and a beta of 1.41.

Theratechnologies (NASDAQ:THTX) last issued its quarterly earnings data on Thursday, October 10th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $22.60 million for the quarter. During the same quarter last year, the business posted ($0.03) EPS. As a group, sell-side analysts anticipate that Theratechnologies will post 0.03 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Theratechnologies stock. Cyndeo Wealth Partners LLC lifted its position in Theratechnologies Inc. (NASDAQ:THTX) by 26.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 131,311 shares of the company’s stock after purchasing an additional 27,191 shares during the period. Cyndeo Wealth Partners LLC owned about 0.29% of Theratechnologies worth $163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.